Tom: This is the news you missed recently:
IGG International, Inc. Appoints David R. Elmaleh, Ph.D. to Science Advisory
Board
PR Newswire - February 21, 1997 08:29
FINANCIAL IGGI AGR MTC PER V%PRN P%PRN
Jump to first matched term
Dr. Elmaleh to Explore Diagnostic Applications of IGG's Core
Carbohydrate-Based Technology
CAMBRIDGE, Mass., Feb. 21 /PRNewswire/ -- IGG International, Inc.
(OTC Bulletin Board: IGGI) announced today it has appointed David R. Elmaleh,
Ph.D., of the Harvard Medical School, to the Company's Scientific Advisory
Board. In addition, Dr. Elmaleh will be collaborating with IGG to research
diagnostic applications for IGG's core carbohydrate-based technology.
"We are pleased to have Dr. Elmaleh on board with us," stated David
Platt, Ph.D., Chief Executive Officer of IGG International. "Dr. Elmaleh
brings to IGG extensive experience in developing in vitro and in vivo
diagnostic agents. He has developed several agents used in conjunction with
PET (Positron Emmision Tomography) and SPECT (Single Photon Emmision
Computerized Tomography). His research on our compounds can open a whole new
line of product opportunities for IGG."
"I am very excited to be working with Dr. Platt and the IGG team," stated
Dr. Elmaleh. "IGG's unique carbohydrate-based compounds look very promising
for therapeutic applications as well as cancer diagnostics. Cancer cells seem
to have a higher expression of receptors for IGG's molecules than normal cells
and their molecules have shown very high affinity for these receptor sites."
Dr. Elmaleh is the Director of Radiopharmaceutical Chemistry, Department
of Radiology, Division of Radiological Services, Massachusetts General
Hospital and is an Associate Professor of Radiology at Harvard Medical School.
He is also an Assistant Professor of Medicinal Chemistry at the College of
Pharmacy and Allied Health Professions in Boston.
Management noted that the Company's lead carbohydrate compound, GBC-590,
recently received Investigational New Drug clearance by the FDA and will begin
human testing in the first quarter of 1997 on cancer patients. In addition,
IGG's agricultural carbohydrate-based fungicide, Elexa, has received
biochemical classification and the Company is currently pursuing EPA
registration.
IGG International, Inc. is a leader in the development of complex
carbohydrate compounds, derived from naturally occurring substances, for
pharmaceutical and agricultural applications. IGGI has two wholly-owned
operating subsidiaries: International Gene Group, Inc. and Agricultural
Glycosystems, Inc. Further information is available on IGG's web site:
www.iggint.com.
Any statements contained in this release that relate to future plans,
events or performance are forward-looking statements that involve risks and
uncertainties, including, but not limited to, risks of product nonapproval or
delays by the FDA, clinical trial results, product development and market
acceptance risks, the results of current and future licensing and other
collaborative relationships, the results of financing efforts, developments
regarding intellectual property rights and litigation, and other risks
identified in the Company's Securities and Exchange Commission filings.
Actual results, events or performance may differ materially. Readers are
cautioned not to place undo reliance on these forward-looking statements,
which speak only as the date hereof. The Company undertakes no obligation to
publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
SOURCE IGG International, Inc.
CONTACT: Richard Salter, V.P., Corporate Development, of IGG
International, Inc., 617-621-3133, or Doug MacDougall of Feinstein Partners
Inc., 617-577-8110
Looks like IGGI has attracted some serious minds to their work. Did you know the MD Anderson Center in Texas just started doing human trials with IGGI's banner compound GBC-590. MD Anderson is one of the foremost cancer research centers in the world. This is definitely an exciting time. I have an e-mail into the co. and waiting to hear back soon. |
